Recent Transactions

10-Aug-23
Undisclosed
United Kingdom flag
Target: 

Clinigen Ltd’s portfolio of Established Medicines

United Kingdom flag
Acquiror: 
CNX Therapeutics

Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners

25-Apr-23
Pending
Undisclosed
United Kingdom flag
Target: 

Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®

United Kingdom flag
Acquiror: 
Advanz Pharma (UK)

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company

20-Mar-23
Pending
Undisclosed
Target: 

Clinigen Ltd’s Lamda Laboratories

Germany flag
Acquiror: 
Adragos Pharma

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO

23-Jan-23
Pending
$200 million
United Kingdom flag
Target: 

Clinigen Ltd’s Proleukin

United States flag
Acquiror: 
Iovance Biotherapeutics

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies

24-Nov-22
Pending
Undisclosed
Target: 

Kyowa Kirin International’s established medicines business

Germany flag
Acquiror: 
Grünenthal

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company

28-Mar-22
Pending
$105 million
United Kingdom flag
Target: 

Acacia Pharma Group plc

United States flag
Acquiror: 
Eagle Pharmaceuticals, Inc.

Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise

28-Mar-22
Pending
~$1.4 billion
United Kingdom flag
Target: 

Theramex

United States flag
Acquiror: 
Carlyle and PAI Partners

Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners

05-Oct-21
$175 million
United Kingdom flag
Target: 

Kao Data Ltd

New Zealand flag
Acquiror: 
Infratil Ltd

Advised Kao Data Ltd, which is jointly owned by Legal & General Group PLC and Noé Group subsidiary Hockham, on raising an initial £120m-£130m growth capital commitment from Infratil Ltd with the objective of creating a £500m data centre platform

27-Jul-21
Undisclosed
United Kingdom flag
Target: 

Pulsant Limited

France flag
Acquiror: 
Antin Infrastructure Partners

Advised Antin Infrastructure Partners on its acquisition of Pulsant from Oak Hill and Scottish Equity Partners. Pulsant is a hybrid cloud specialist, with a nationwide network of 10 data centres across the UK delivering secure, scalable and resilient cloud, colocation and networking services

14-Jul-21
Undisclosed
Target: 

New Day Aluminum LLC

United Kingdom flag
Acquiror: 
Concord Resources Ltd.

Advised DADA Holdings on the sale of its majority stake in New Day Aluminum LLC to Concord Resources Ltd.

27-May-21
$1.4 billion
United Kingdom flag
Target: 

Equiniti Group PLC

United States flag
Acquiror: 
Siris Capital Group LLC

Advised Siris Capital, a private equity firm focused on the technology sector, on its recommended 180p cash offer for Equiniti Group PLC, a technology-led services and payments specialist

29-Dec-20
$110 million
United States flag
Target: 

Biogix, Inc.

United Kingdom flag
Acquiror: 
Alliance Pharma plc

Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc

22-Sep-20
$NA
Sweden flag
Target: 

VX Fiber

United Kingdom flag
Acquiror: 
AMP Capital

Advised VX Fiber, an international infrastructure and technology business focused on Fibre-to-the-Home networks, on its sale to the infrastructure fund AMP Capital

01-Jul-20
$225 million
United Kingdom flag
Target: 

Cello Health plc

United States flag
Acquiror: 
Arsenal Capital Partners

Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States

10-Jun-20
$134 million
Saudi Arabia Flag
Target: 

Equity stake in Bupa Arabia

United Kingdom flag
Acquiror: 
Bupa Ltd.

Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia,  the largest health insurance provider in the Kingdom of Saudi Arabia

02-Mar-20
$NA
United Kingdom flag
Target: 

Global rights (excluding North America) to ThermaCare (United Kingdom)

Italy flag
Acquiror: 
Angelini Pharma

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma

20-Feb-20
$NA
United Kingdom flag
Target: 

Asia and US rights to Physiogel

Korea flag
Acquiror: 
LG Household & Health Care

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd

19-Dec-18
$NA
United States flag
Target: 

Pfizer Inc. Consumer Health Business

United Kingdom flag
Acquiror: 
GlaxoSmithKline plc

Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture

03-Dec-18
$4.0 billion
United Kingdom flag
Target: 

Assets owned by GlaxoSmithKline plc

Acquiror: 
Unilever plc / Hindustan Unilever Limited

Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited

27-Mar-18
$13.0 billion
Switzerland flag
Target: 

Novartis AG’s 36.5% stake in Consumer Health Joint Venture

United Kingdom flag
Acquiror: 
GlaxoSmithKline plc

Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture

22-Dec-17
$5.3 billion
United Kingdom flag
Target: 

Ladbrokes Coral Group PLC

United Kingdom flag
Acquiror: 
GVC Holdings PLC

Advised Ladbrokes Coral Group PLC, a leading multi-channel sports betting and gaming company, on a recommended offer from GVC Holdings PLC, a multi-national online sports betting and gaming company

08-Dec-17
$NA
United Kingdom flag
Target: 

London & Country Mortgages Limited (“L&C”)

United Kingdom flag
Acquiror: 
Experian plc

Advised Experian plc, the world’s leading global information services company, in connection with the acquisition of a 25% stake in L&C, the UK’s largest fee free mortgage adviser

12-Jul-17
$227 million
United States flag
Target: 

Wells Fargo Share Registration & Service business

United Kingdom flag
Acquiror: 
Equiniti Group plc

Advised Equiniti Group plc, a UK based specialist technology outsourcer providing non-discretionary payment and administration services, on the acquisition of Wells Fargo's Shareowner Services business, and acted as joint sponsor to Equiniti's associated £122 million rights issue

11-May-17
$245 million
Saudi Arabia Flag
Target: 

Equity stake in Bupa Arabia

United Kingdom flag
Acquiror: 
Bupa Ltd.

Advised Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, one of the largest health insurance providers in the Kingdom of Saudi Arabia

03-Apr-17
$400 million
United States flag
Target: 

Cheetahmail

United States flag
Acquiror: 
Vector Capital

Advised Vector Capital on the acquisition of Cheetahmail from Experian plc

Pages

show all